IRIS
SANTORO, MARIA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 25.359
EU - Europa 3.149
AS - Asia 2.959
SA - Sud America 406
AF - Africa 62
Continente sconosciuto - Info sul continente non disponibili 12
OC - Oceania 1
Totale 31.948
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 25.248
SG - Singapore 1.782
IT - Italia 578
DE - Germania 499
CN - Cina 420
BR - Brasile 366
IE - Irlanda 348
SE - Svezia 339
HK - Hong Kong 335
UA - Ucraina 303
RU - Federazione Russa 241
KR - Corea 234
PL - Polonia 217
FR - Francia 182
GB - Regno Unito 152
FI - Finlandia 110
CA - Canada 90
NL - Olanda 54
AT - Austria 43
ID - Indonesia 41
VN - Vietnam 24
BE - Belgio 20
CZ - Repubblica Ceca 18
IN - India 17
CM - Camerun 15
ES - Italia 14
JP - Giappone 14
BD - Bangladesh 13
IQ - Iraq 13
ZA - Sudafrica 13
TR - Turchia 11
EU - Europa 10
PK - Pakistan 10
EC - Ecuador 9
PH - Filippine 9
CH - Svizzera 8
MX - Messico 8
RO - Romania 8
CL - Cile 7
MA - Marocco 7
VE - Venezuela 7
UZ - Uzbekistan 6
CO - Colombia 5
AE - Emirati Arabi Uniti 4
AR - Argentina 4
BO - Bolivia 4
EG - Egitto 4
JM - Giamaica 4
KE - Kenya 4
AO - Angola 3
AZ - Azerbaigian 3
DZ - Algeria 3
GR - Grecia 3
IR - Iran 3
JO - Giordania 3
PA - Panama 3
PT - Portogallo 3
SA - Arabia Saudita 3
TN - Tunisia 3
TZ - Tanzania 3
AL - Albania 2
AM - Armenia 2
BG - Bulgaria 2
GH - Ghana 2
IL - Israele 2
KG - Kirghizistan 2
NG - Nigeria 2
PE - Perù 2
TT - Trinidad e Tobago 2
UG - Uganda 2
A1 - Anonimo 1
A2 - ???statistics.table.value.countryCode.A2??? 1
BH - Bahrain 1
BY - Bielorussia 1
CR - Costa Rica 1
CY - Cipro 1
DK - Danimarca 1
DM - Dominica 1
DO - Repubblica Dominicana 1
EE - Estonia 1
HN - Honduras 1
LB - Libano 1
LT - Lituania 1
MN - Mongolia 1
NP - Nepal 1
NZ - Nuova Zelanda 1
OM - Oman 1
PS - Palestinian Territory 1
PY - Paraguay 1
QA - Qatar 1
SC - Seychelles 1
SK - Slovacchia (Repubblica Slovacca) 1
UY - Uruguay 1
Totale 31.948
Salva come PNG Salva come JPEG
Città #
Woodbridge 6.937
Wilmington 6.847
Houston 5.409
Fairfield 891
Singapore 875
Chandler 551
Ann Arbor 508
Ashburn 431
Seattle 383
Hong Kong 330
Dublin 316
Cambridge 305
Rome 254
Jacksonville 253
Medford 230
Beijing 222
Kraków 213
Santa Clara 194
Dearborn 176
New York 139
Lawrence 108
The Dalles 98
Council Bluffs 76
San Diego 59
Moscow 53
Zhengzhou 53
Nuremberg 52
Menlo Park 49
Dundas 48
Milan 48
Munich 43
Jakarta 41
Mülheim 41
London 34
Creede 30
São Paulo 30
Helsinki 28
Boardman 25
Los Angeles 25
Falls Church 24
Phoenix 24
Dong Ket 20
Brussels 18
Palermo 18
Vienna 18
Colorado Springs 17
San Francisco 16
Toronto 15
Lappeenranta 14
Brno 13
Nanjing 13
Norwalk 13
Seoul 13
Florence 12
Palo Alto 12
Redwood City 12
University Park 12
Amsterdam 11
Guangzhou 11
Cedarhurst 10
Kunming 10
Mountain View 10
Rio de Janeiro 10
San Jose 10
Belo Horizonte 9
Dallas 9
North Bergen 9
Verona 9
Baghdad 8
Manila 7
Porto Alegre 7
Chicago 6
Hefei 6
Jiaxing 6
Manitou Springs 6
Marcianise 6
Ottawa 6
Saint Petersburg 6
Salvador 6
Atlanta 5
Brasília 5
Durban 5
Frankfurt am Main 5
Hamilton 5
Hounslow 5
Jinan 5
Nürnberg 5
Olomouc 5
Parma 5
Santo André 5
Shanghai 5
Siena 5
Tokyo 5
Turku 5
Vancouver 5
Acton 4
Afragola 4
Belford Roxo 4
Berlin 4
Boston 4
Totale 26.967
Salva come PNG Salva come JPEG
Nome #
Is there any potential for first-line etravirine use? Analysis from a large data set of antiretroviral therapy-naive HIV-infected patients undergoing resistance test 560
HCV NS3 sequencing as a reliable and clinically useful tool for the assessment of genotype and resistance mutations for clinical samples with different HCV-RNA levels 521
The Genotypic False Positive Rate Determined by Population V3-Sequencing can Predict the Burden of X4 Quasispecies Detected by Pyrosequencing 501
Lower prevalence of drug resistance mutations at first-line virological failure to first-line therapy with atripla vs. tenofovirRemtricitabine/lamivudineRefavirenz administered on a multiple tablet therapy 499
Two different patterns of mutations are involved in the genotypic resistance score for atazanavir boosted versus unboosted by ritonavir in multiple failing patients 461
Characterization and structural analysis of novel mutations in human immunodeficiency virus type 1 reverse transcriptase involved in the regulation of resistance to nonnucleoside inhibitors 458
Comet assay and micronucleus test in circulating erythrocytes of Cyprinus carpio specimens exposed in situ to lake waters treated with disinfectants for potabilization 454
Drug-resistance development differs between HIV-1-infected patients failing first-line antiretroviral therapy containing nonnucleoside reverse transcriptase inhibitors with and without thymidine analogues 448
Viro-immunological response of drug-naive HIV-1-infected patients starting a first-line regimen with viraemia >500,000 copies/ml in clinical practice 446
Comparative Analysis of Drug Resistance Among B and the Most Prevalent Non-B HIV Type 1 Subtypes (C, F, and CRF02_AG) in Italy 444
'Sentinel' mutations in standard population sequencing can predict the presence of HIV-1 reverse transcriptase major mutations detectable only by ultra-deep pyrosequencing 441
Specific mutations in the C-terminus domain of HBV surface antigen significantly correlate with low level of serum HBV-DNA in patients with chronic HBV infection 437
Population dynamics of HIV-1 subtype B in a cohort of men-having-sex-with-men in Rome, Italy 435
The lowest X4 Geno2Pheno false-positive rate is associated with greater CD4 depletion in HIV-1 infected patients 434
Involvement of novel human immunodeficiency virus type 1 reverse transcriptase mutations in the regulation of resistance to nucleoside inhibitors 434
Structural modifications induced by specific HIV-1 protease-compensatory mutations have an impact on the virological response to a first-line lopinavir/ritonavir-containing regimen 433
Specific enfuvirtide-associated mutational pathways in HIV-1 Gp41 are significantly correlated with an increase in CD4(+) cell count, despite virological failure 431
Viro-immunologic response to ritonavir-boosted or unboosted atazanavir in a large cohort of multiply treated patients: the CARe Study 427
Comparative evaluation of subtyping tools for the surveillance of newly emerging HIV-1 strains 426
Different evolution of genotypic resistance profiles to emtricitabine versus lamivudine in tenofovir-containing regimens 414
Specific mutations in HIV-1 gp41 are associated with immunological success in HIV-1-infected patients receiving enfuvirtide treatment 407
The multifactorial pathways towards resistance to the cytosine analogues emtricitabine and lamivudine: Evidences from literature 404
Temporal characterization of drug resistance associated mutations in HIV-1 protease and reverse transcriptase in patients failing antiretroviral therapy 402
Non-B HIV type 1 subtypes among men who have sex with men in Rome, Italy 401
Performance evaluation of an in-house human immunodeficiency virus type-1 protease-reverse transcriptase genotyping assay in Cameroon 401
Virological response and resistance profile in HIV-1-infected patients starting darunavir-containing regimens 393
Molecular Epidemiology of HIV Type 1 CRF02_AG in Cameroon and African Patients Living in Italy 391
Dynamics of NRTI resistance mutations during therapy interruption 391
'Sentinel' mutations in standard population sequencing can predict the presence of HIV-1 reverse transcriptase major mutations detectable only by ultra-deep pyrosequencing 390
HIV-1 R5+ /X4- tropic viruses can be inhibited in vitro as well as in vivo by maraviroc: a refined analysis of patients enrolled in the Phase IIb study A4001029 389
Characterization of drug-resistance mutations in HIV type 1 isolates from drug-naive and ARV-treated patients in Bulgaria 388
HIV-1 Drug Susceptibility to Potential Second- and Third-Line Antiretroviral Regimens among Cameroonian Patients: Evidence from a Cross-sectional Design 386
Docking Analysis and Resistance Evaluation of Clinically Relevant Mutations Associated with the HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors Nevirapine, Efavirenz and Etravirine 384
Short communication: Population-based surveillance of HIV-1 drug resistance in cameroonian adults initiating antiretroviral therapy according to the world health organization guidelines 382
Genotypic resistance test in proviral DNA can identify resistance mutations never detected in historical genotypic test in patients with low level or undetectable HIV-RNA 380
Circulation of HIV-1 CRF02_AG among MSM population in central Italy: a molecular epidemiology-based study 379
Temporal change in the use of genotypic resistance testing over the years 1999--2003 377
High sequence conservation of human immunodeficiency virus type 1 reverse transcriptase under drug pressure despite the continuous appearance of mutations 377
Efficacy of etravirine combined with darunavir or other ritonavir-boosted protease inhibitors in HIV-1-infected patients: An observational study using pooled European cohort data 377
Different evolution of genotypic resistance profiles to emtricitabine versus lamivudine in tenofovir-containing regimens. 374
HIV-1 integrase genotyping is reliable and reproducible for routine clinical detection of integrase resistance mutations even in patients with low-level viraemia 374
A very low geno2pheno false positive rate is associated with poor viro-immunological response in drug-naïve patients starting a first-line HAART. 373
Reliability and clinical relevance of the HIV-1 drug resistance test in patients with low viremia levels 371
An update on integrase inhibitors: new opportunities for a personalized therapy? The NEXTaim Project 368
Clinical relevance of genotypic resistance testing today 366
Improved darunavir genotypic mutation score predicting treatment response for patients infected with HIRaben-1 subtype B and non-subtype B receiving a salvage regimen 365
Use of novel antiretroviral agents in rescue regimens: a case of early virological failure to raltegravir 358
The genotypic false positive rate determined by V3 population sequencing can predict the burden of HIV-1 CXCR4-using species detected by pyrosequencing 357
Next-generation sequencing provides an added value in determining drug resistance and viral tropism in Cameroonian HIV-1 vertically infected children 357
Genotypic tropism testing in HIV-1 proviral DNA can provide useful information at low-level viremia 355
Interpretation of genotypic HIV-1 resistance to darunavir and virological response: validation of available systems and of a new score 355
HIV-1 non-B subtypes in Italy: a growing trend 353
High Burden of HBV-Infection and Atypical HBV Strains among HIV-infected Cameroonians 352
HIV-1 Genetic Variability and Clinical Implications 348
Drug Resistance Among Drug-naive and First-line Antiretroviral Treatment-failing Children in Cameroon 347
Improving the prediction of virological response to tipranavir: the development and validation of a tipranavir-weighted mutation score 347
Pre-existent NRTI and NNRTI resistance impacts on maintenance of virological suppression in HIV-1-infected patients who switch to a tenofovir/emtricitabine/rilpivirine single-tablet regimen 343
Characterization of drug resistance mutations in naive and ART-treated patients infected with HIV-1 in Yaounde, Cameroon 340
Rare occurrence of doravirine resistance-associated mutations in HIV-1-infected treatment-naive patients 332
Impact of HIV-1 tropism on the emergence of non-AIDS events in HIV-infected patients receiving fully suppressive antiretroviral therapy 329
Integrase strand transfer inhibitor-based regimen is related with a limited HIV-1 V3 loop evolution in clinical practice 327
Dynamics and phylogenetic relationships of HIV-1 transmitted drug resistance according to subtype in Italy over the years 2000-14 322
The Lowest X4 Geno2Pheno-False Positive Rate Is Associated with Greater CD4-Depletion 320
Genetic divergence of HIV-1 B subtype in Italy over the years 2003–2016 and impact on CTL escape prevalence 311
Impact of pre-therapy viral load on virological response to modern first-line HAART 303
The HIV-1 reverse transcriptase polymorphism A98S improves the response to tenofovir disoproxil fumarate + emtricitabine-containing HAART both in vivo and in vitro 299
Recent transmission clustering of HIV-1 C and CRF17-BF strains characterized by NNRTI-related mutations among newly diagnosed men in central Italy 283
Very high pre-therapy viral load is a predictor of virological rebound in HIV-1-infected patients starting a modern first-line regimen 278
Resistance detected in PBMCs predicts virological rebound in HIV-1 suppressed patients switching treatment 273
Quantification of HIV-DNA and residual viremia in patients starting ART by droplet digital PCR: Their dynamic decay and correlations with immunological parameters and virological success 269
Characterisation of HIV-1 molecular transmission clusters among newly diagnosed individuals infected with non-B subtypes in Italy 219
New resistance mutations to nucleoside reverse transcriptase inhibitors at codon 184 of HIV-1 reverse transcriptase (M184L and M184T) 195
HIV MDR is still a relevant issue despite its dramatic drop over the years 192
Is the rate of virological failure to cART continuing to decline in recent calendar years? 189
Genetic diversity of HIV type 1 in Montenegro 174
Evaluation of HIV-1 integrase resistance emergence and evolution in patients treated with integrase inhibitors 172
Identification of gp120 polymorphisms in HIV-1 B subtype potentially associated with resistance to fostemsavir 171
HIV-1 drug resistance testing is essential for heavily-treated patients switching from first- to second-line regimens in resource-limited settings: Evidence from routine clinical practice in Cameroon 157
Prevalence of doravirine-associated resistance mutations in HIV-1-infected antiretroviral-experienced patients from two large databases in France and Italy 155
Italian expert panel consensus statements on two-drug antiretroviral regimens to treat naïve and virologically suppressed HIV-1 infected patients 141
CEDRIC-HIV: la checklist per gli studi sulla resistenza ai farmaci anti-HIV 133
Viral suppression in adults, adolescents and children receiving antiretroviral therapy in Cameroon: Adolescents at high risk of virological failure in the era of "test and treat" 126
Global epidemiology of drug resistance after failure of WHO recommended first-line regimens for adult HIV-1 infection: A multicentre retrospective cohort study 118
Impact of transmitted HIV-1 drug resistance on the efficacy of firstline antiretroviral therapy with two nucleos(t)ide reverse transcriptase inhibitors plus an integrase inhibitor or a protease inhibitor 81
Detection of Gag C-terminal mutations among HIV-1 non-B subtypes in a subset of Cameroonian patients 79
Genetic Determinants in a Critical Domain of NS5A Correlate with Hepatocellular Carcinoma in Cirrhotic Patients Infected with HCV Genotype 1b 78
High performance of integrase genotyping on diverse HIV-1 clades circulating in Cameroon: toward a successful transition to dolutegravir-based regimens in low and middle-income countries 77
Current status of antivirals and druggable targets of SARS CoV-2 and other human pathogenic coronaviruses 76
Frequency of atypical mutations in the spike glycoprotein in SARS-CoV-2 circulating from July 2020 to July 2022 in central Italy: a refined analysis by Next Generation Sequencing 73
Impact of analytical treatment interruption on burden and diversification of HIV peripheral reservoir: a pilot study 72
Viral resistance burden and APOBEC editing correlate with virological response in heavily treatment-experienced people living with multi-drug resistant HIV 70
Baseline integrase drug resistance mutations and conserved regions across HIV-1 clades in Cameroon: implications for transition to dolutegravir in resource-limited settings 67
Simplification to High Genetic Barrier 2-Drug Regimens in People Living With HIV Harboring 4-Class Resistance Enrolled in the PRESTIGIO Registry 64
Bictegravir/emtricitabine/tenofovir alafenamide ensures high rates of virological suppression maintenance despite previous resistance in PLWH who optimize treatment in clinical practice 63
Genotypic HIV-1 tropism determination might help to identify people with exhausted treatment options and advanced disease 63
Prevalence and factors associated with HIV-1 multidrug resistance over the past two decades in the Italian Arca database 58
Evaluation of virological response and resistance profile in HIV-1 infected patients starting a first-line integrase inhibitor-based regimen in clinical settings 57
Impact of pre-existent drug resistance on virological efficacy of single tablet regimens in people living with HIV 56
Alarming rates of virological failure and HIV-1 drug resistance amongst adolescents living with perinatal HIV in both urban and rural settings: evidence from the EDCTP READY-study in Cameroon 56
Mutational Correlates of Virological Failure in Individuals Receiving a WHO-Recommended Tenofovir-Containing First-Line Regimen: An International Collaboration 55
Totale 30.239
Salva come PNG Salva come JPEG
Categoria #
all - tutte 86.409
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 86.409
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020523 0 0 0 0 0 0 0 0 0 0 0 523
2020/20214.577 489 544 524 624 419 515 599 407 84 121 152 99
2021/20221.345 56 76 83 49 59 91 54 37 346 129 57 308
2022/20231.684 170 137 87 178 159 348 113 168 137 37 102 48
2023/2024683 80 18 29 24 53 126 37 18 19 138 11 130
2024/20254.726 160 906 460 241 141 258 601 195 421 294 541 508
Totale 32.686